Anastrozole 1 - Advar Pharma

Anastrozole entered the pharmaceutical market in 1995, developed by Zeneca as a response to the limitations of older anti-estrogen therapies like tamoxifen. Its design focused on inhibiting aromatase, the enzyme responsible for converting androgens into estrogens. The drug rose to prominence after the ATAC study — one of the largest trials of its kind — demonstrated its effectiveness in reducing breast cancer recurrence. As a result, it became a standard in hormonal oncology and later gained popularity among male athletes for its potent estrogen-suppressing effects.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Anastrozole 1 by Advar Pharma, consult with your doctor or healthcare professional.